Background
Patients
infected with human immunodeficiency virus (HIV) are living longer due to the
availability of more potent treatments. However, prescription of antibiotics to
treat or prevent infections in these patients may increase the likelihood of
co-infection with antibiotic-resistant species.
Aim
To
compare antimicrobial susceptibility of Helicobacter pylori (H. pylori) in HIV-positive and HIV-negative patients
and assess risk-factors for resistance.
Methods
We
prospectively collected data from consecutive HIV-positive and HIV-negative
patients undergoing upper gastrointestinal endoscopy. Patients with H. pylori-positive
gastric biopsies who had never received H. pylori treatment were included.
Results
Of
the 353 patients included, 93 were HIV-positive and 260 HIV-negative. Among the
HIV-positive patients, 56 (60%) had been infected for <10 years, the median
CD4+ count was 493 cells/μl and median viral load was 61 copies/mL; 66 (71%)
were receiving antiretroviral therapy. HIV-positive patients were more often
male (p = 0.009), had a lower body mass index (p<0.0001), and had less
frequently received antibiotics during the 12-months prior to the endoscopy
(p<0.0001) than HIV-negative patients. HIV-positive patients were more
likely to have H. pylori resistant to levofloxacin (p = 0.0004),
metronidazole (p = 0.01), or multiple antibiotics (p = 0.006). HIV-positive
Black Africans were more likely to have resistant strains than were
HIV-negative Black Africans (p = 0.04). Ethnicity and HIV status were
independent risk factors for H. pylori resistance in all patients and acquired
immune deficiency syndrome (AIDS) and sex were risk factors in HIV-positive
patients.
Conclusions
There was a higher prevalence of primary H. pylori-resistant
strains in HIV-positive than in HIV-negative patients. AIDS and sex were
predictors of H. pylori resistance in HIV-positive patients.
Below: Summary of primary resistance of H. pylori in HIV-positive and HIV-negative patients
Full article at: http://goo.gl/H023gc
By:
Marcel Nkuize, Vinciane Muls, Michel Buset
Department of Gastroenterology
and Hepatology, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels,
Belgium
Stéphane De Wit, Marc Delforge
Division of Infectious Diseases,
CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium
Véronique Y. Miendje Deyi
Department of Microbiology, CHU
Brugmann, Université Libre de Bruxelles, Brussels, Belgium
Guy B. Cadière
Department of Digestive Surgery,
CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium
More at: https://twitter.com/hiv_insight
No comments:
Post a Comment